About Us

Mesenbio delivers next-generation medicine.

Mesenbio is a preclinical stage biopharmaceutical company from the University of York. Our Cell Line Extracellular Vesicle Release (CLEVR) platform enables us to pursue a varied therapeutic pipeline by addressing the most prevalent bottleneck in extracellular vesicle therapeutics: consistency.

We leverage our platform to produce a consistent, endless supply of therapeutically exciting extracellular vesicles. Our aim is to transform medicine by unlocking extracellular vesicles as a novel treatment modality.

We have shown that our cells produce naturally bioactive extracellular vesicles with combined anti-inflammatory and pro-regenerative potential, and are pursuing an internal pipeline to address musculoskeletal disease that takes advantage of this unique capability.

CLEVR can also enable discovery and development of interventions for other indications, and we are happy to discuss potential synergies with new partners.

Meet the Team

  • Dr. David Kuntin

    FOUNDER / CEO
    david@mesenbio.net

    David Kuntin is CEO and co-founder of Mesenbio. With expertise in biology and industrial process technology, he drives groundbreaking research and innovation. David's strategic leadership has positioned Mesenbio as a prominent player in the industry. His multidisciplinary approach fosters collaboration and ensures the successful translation of scientific discoveries into practical applications. Under his guidance, Mesenbio continues to push the boundaries of biotechnology, making significant contributions to the field.

  • Prof. Paul Genever

    FOUNDER / CSO
    paul@mesenbio.net

    With over 20 years of experience in the field, Paul Genever is a distinguished professor at the University of York's Department of Biology. He is widely recognized as a leading expert in mesenchymal stem cell biology and regenerative medicine. Paul's extensive knowledge and expertise have been instrumental in advancing our understanding of tissue repair and regeneration. Having authored over 100 peer-reviewed publications, he has made significant contributions to the scientific community. As a mentor, Paul inspires and guides the next generation of scientists, leaving a lasting impact on the field. His dedication and wealth of experience solidify his standing as a prominent figure in stem cell biology and regenerative medicine.

  • Dr. Dave Mentlak

    SENIOR SCIENTIST
    dave.mentlak@mesenbio.net

    Dave has a strong background in biotechnology, with eight years of experience leading projects focussed on therapeutic antibody production in Chinese Hamster Ovary (CHO) cells. His previous role was at the interface between academia and industry, and focussed on increasing secretory capacity, maintaining cell viability and improving product quality attributes through glycoengineering. Dave has developed a wealth of experience in bioprocessing, molecular biology and analytical techniques that will help drive the growth of biotherapeutics with Mesenbio.

  • Dr. Ryan Farley

    SCIENTIST II
    ryan.farley@mesenbio.net

    With a background in molecular virology and experience in biopharmaceutical research and process design, Ryan hopes to provide innovative solutions to Mesenbio. From large scale manufacturing of cell and gene therapy vectors to developing next generation biopharmaceutical filters. Ryan went on to complete a PhD in molecular virology, focusing on enhancing the packaging of therapeutic RNAs into virus-like particle vectors for gene therapy applications. Ryan hopes to combine his experiences and continue growing at Mesenbio.